A Phase I Study of INC280 in Japanese Patients With Advanced Solid Tumors
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
INC280 will be administered to Japanese patients with advanced soid tumors whose disease has progressed despite standard therapy or for whom no standard therapy exists. The trial will assess the safety and tolerability and determine the maximum tolerated dose (MTD) on INC280
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years and older (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Advanced solid tumors that are refractory to currently available therapies or for which no effective treatment is available.
Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 2
Good organ (hepatic, kidney, BM) function at screening/baseline visit.
Symptomatic CNS metastases that are neurologically unstable or requiring increasing doses of steroids to control CNS disease.
Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of INC280.
Undergone a bone marrow or solid organ transplant.
Women who are pregnant or breast feeding.
Other protocol-defined inclusion/exclusion criteria may apply